Introduction and Objective: ASC47 (selective THR-β agonist) is an adipose-targeted, once-monthly subcutaneously (SQ) injected, muscle-preserving weight loss drug candidate for the treatment of obesity, discovered and developed in-house at Ascletis. This study in diet-induced obese (DIO) mice demonstrated a powerful synergy in weight loss and muscle preservation when combining ASC47 and semaglutide.Methods: C57BL/6J mice were fed a high-fat diet for 16 weeks and received different treatments for 28 days. Body weight and food intake were recorded daily. Body composition was assessed by EchoMRI weekly.Results: ASC47 low dose combination 1 demonstrated superior weight loss compared to semaglutide monotherapy, showing an average total body weight reduction of 36.2%, a 56.7% greater reduction in body weight compared to semaglutide monotherapy. At the end of treatment, the percentage of total muscle mass over the total body weight of obese mice treated with ASC47 low dose combination treatments (68.8%) were close to healthy non-obese mice (66.0%), indicating healthy weight loss. Semaglutide monotherapy was unable to restore body composition to healthy levels.Conclusion: ASC47 low dose combination treatments were well tolerated in obese mice and produced a significant and healthy WL.
J. Wu: Employee; Ascletis Pharma (China) Co., Limited. C. Wu: Employee; an affiliate of Ascletis Pharma (China) Co., Limited,.
Ascletis Pharma (China) Co., Limited
Source link
Leave a Reply